The value of robot-assisted gastrectomy in the treatment of gastric cancer: a systematic review and meta-analysis - Top-Institutions - MDSpire

The value of robot-assisted gastrectomy in the treatment of gastric cancer: a systematic review and meta-analysis

  • By

  • Lei Chen

  • Qian Wang

  • Wanbin He

  • Yonghong Wang

  • Yaping Li

  • Jie Dan

  • June 9, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Surgical Oncology
    • Gastrointestinal Surgery

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Surgical Oncology
    • Gastrointestinal Surgery

  • #3

    Italian Research Group for Gastric Cancer (GIRCG)
    Italian Research Group for Gastric Cancer (GIRCG)

    Italy

    Key Differentiators

    • Gastric Cancer Research
    • Surgical Oncology

  • #4

    The Second Affiliated Hospital of Dalian Medical University
    The Second Affiliated Hospital of Dalian Medical University

    Dalian, Liaoning

    Key Differentiators

    • Surgical Oncology
    • Minimally Invasive Surgery

  • #5

    University of Siena
    University of Siena

    Siena, Tuscany

    Key Differentiators

    • Surgical Oncology
    • Robotic Surgery

Original Source(s)

The value of robot-assisted gastrectomy in the treatment of gastric cancer: a systematic review and meta-analysis

  • by Lei Chen, Qian Wang, Wanbin He, Yonghong Wang, Yaping Li, Jie Dan

  • June 9, 2026

Related Content

Alkaloids mediated regulation of microRNA in cancer: molecular insights and emerging therapeutic strategies

Neurofilament light and glial fibrillary acidic protein do not reflect neuronal or glial damage during different intracranial radiotherapy regimes: a pilot study

This Week’s CGT News: Promising Data for In Vivo CAR T

Legend and Kelonia reveal 100 percent response rates in phase 1 trials, dual CAR T opens doors for kidney transplant patients, and iPDSC therapy beefs up failing hearts

  • June 8, 2026

  • 6 min